In a nutshell This study examined whether chromosomal abnormalities at diagnosis can predict treatment outcomes with TKIs in chronic myeloid leukemia (CML). Researchers reported similar long-term treatment outcomes in patients with and without chromosomal abnormalities at diagnosis. Some background CML is a disease in which the bone marrow makes...
Read More
In a nutshell This study analyzed the results of 37 studies comparing myeloablative therapy and reduced intensity conditioning (RIC) before stem cell transplantation in patients with chronic lymphocytic leukemia (CLL). This study concluded that RIC was associated with lower mortality and better survival compared to myeloablative therapy. Some...
Read More
In a nutshell This study examined outcomes after discontinuation of nilotinib (Tasigna) in patients with chronic myeloid leukemia (CML). Researchers reported that over half of CML patients were able to sustain a deep treatment response for at least 48 weeks after stopping nilotinib. Some background Major molecular response (MMR) is a response to...
Read More
In a nutshell This study reviewed evidence of novel agents in the treatment of chronic myeloid leukemia (CML). Some background CML is a disease in which the bone marrow makes too many mature and immature white blood cells. It is typically a slowly progressing disease that occurs mainly during or after middle age. Most patients are diagnosed in the...
Read More
In a nutshell This study examined whether imatinib (Gleevac) affects the fertility of men with chronic myeloid leukemia (CML). Researchers concluded that imatinib reduced sperm density, sperm count, sperm survival and activity when compared to healthy control participants. Some background CML has three phases: chronic, accelerated, and...
Read More
In a nutshell This study examined stem cell transplant outcomes across acute myeloid leukemia (AML) patients with different disease status. Researchers reported superior survival after a stem cell transplant among patients in second complete remission. Some background Stem cell transplantation is considered the most effective therapy for...
Read More
In a nutshell This study aimed to investigate the impact of smoking on survival and progression of disease in patients with chronic myeloid leukemia. This study concluded that smoking has a negative impact on survival and progression of disease in patients with chronic myeloid leukemia. Some background Chronic myeloid leukaemia (CML)...
Read More
In a nutshell This study examined the effectiveness of different doses of nilotinib (Tasigna) in patients with newly diagnosed chronic myeloid leukemia in chronic phase. This study concluded that nilotinib was safe and effective in treating chronic myeloid leukemia. Some background Chronic myeloid leukemia is a cancer where the...
Read MoreIn a nutshell This paper compared ponatinib (Iclusib) and stem cell transplantation in leukemia patients with an abnormality on the T315I gene. Patients with acute lymphoblastic leukaemia (ALL) positive for the Philadelphia chromosome and patients with chronic myeloid leukaemia (CML) were studied. Authors reported improved survival with...
Read More
In a nutshell This study examined the extent and effect of complete treatment response (on a molecular level) in patients treated with imatinib (Gleevac) for chronic myeloid leukemia (CML). Researchers reported that a high proportion of patients treated with imatinib reached complete molecular remission, particularly when given at a high dose. Complete...
Read More
In a nutshell This study examined the effect of dose reductions or interruptions on the effectiveness of dasatinib (Sprycel) and nilotinib (Tasigna). The authors concluded that dose reductions or treatment breaks did not affect response or survival rates in chronic myeloid leukemia (CML) patients. Some background The tyrosine kinase inhibitor...
Read More
In a nutshell This study compared the rates of peripheral arterial occlusive disease (PAOD) in chronic myeloid leukemia (CML) patients treated with different therapies. The authors concluded that nilotinib (Tasigna) was associated with higher rates of PAOD than other treatments. Some background Tyrosine kinase inhibitors (TKIs) are now the...
Read More
